Frederik H Verbrugge1, Pieter Martens2, Wilfried Mullens2. 1. Department of Cardiology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, 3600, Genk, Belgium. frederik.verbrugge@zol.be. 2. Department of Cardiology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, 3600, Genk, Belgium.
Abstract
PURPOSE OF REVIEW: This review aims to summarize the renal effects of sodium-glucose transporter-2 (SGLT-2) inhibitors and their potential implications in heart failure pathophysiology. RECENT FINDINGS: In patients with diabetes and established atherosclerosis, the SGLT-2 inhibitor empagliflozin versus placebo significantly reduced the rate of heart failure admissions with 35%. Moreover, empagliflozin slowed kidney disease progression and reduced the need for renal replacement therapy. SGLT-2 inhibitors inhibit proximal tubular sodium and chloride reabsorption, leading to increased nephron flux throughout the distal renal tubules, most notably at the level of the macula densa. Afferent arteriolar vasoconstriction is promoted through tubulo-glomerular feedback and reduces glomerular capillary hydrostatic pressure, relieving podocyte stress and explaining renal preservation. Further, plasma volume is contracted and natriuresis promoted without inducing neurohumoral activation. Finally, SGLT-2 inhibitors may improve endothelial function and energy metabolism efficiency. Together, these promising features place them as a potential novel treatment for heart failure.
PURPOSE OF REVIEW: This review aims to summarize the renal effects of sodium-glucose transporter-2 (SGLT-2) inhibitors and their potential implications in heart failure pathophysiology. RECENT FINDINGS: In patients with diabetes and established atherosclerosis, the SGLT-2 inhibitor empagliflozin versus placebo significantly reduced the rate of heart failure admissions with 35%. Moreover, empagliflozin slowed kidney disease progression and reduced the need for renal replacement therapy. SGLT-2 inhibitors inhibit proximal tubular sodium and chloride reabsorption, leading to increased nephron flux throughout the distal renal tubules, most notably at the level of the macula densa. Afferent arteriolar vasoconstriction is promoted through tubulo-glomerular feedback and reduces glomerular capillary hydrostatic pressure, relieving podocyte stress and explaining renal preservation. Further, plasma volume is contracted and natriuresis promoted without inducing neurohumoral activation. Finally, SGLT-2 inhibitors may improve endothelial function and energy metabolism efficiency. Together, these promising features place them as a potential novel treatment for heart failure.
Authors: Jeffrey M Testani; Meredith A Brisco; Jennifer Chen; Brian D McCauley; Chirag R Parikh; W H Wilson Tang Journal: J Am Coll Cardiol Date: 2013-06-07 Impact factor: 24.094
Authors: Robert J Mentz; Susanna R Stevens; Adam D DeVore; Anuradha Lala; Justin M Vader; Omar F AbouEzzeddine; Prateeti Khazanie; Margaret M Redfield; Lynne W Stevenson; Christopher M O'Connor; Steven R Goldsmith; Bradley A Bart; Kevin J Anstrom; Adrian F Hernandez; Eugene Braunwald; G Michael Felker Journal: JACC Heart Fail Date: 2014-10-31 Impact factor: 12.035
Authors: Tadahiro Shimazu; Matthew D Hirschey; John Newman; Wenjuan He; Kotaro Shirakawa; Natacha Le Moan; Carrie A Grueter; Hyungwook Lim; Laura R Saunders; Robert D Stevens; Christopher B Newgard; Robert V Farese; Rafael de Cabo; Scott Ulrich; Katerina Akassoglou; Eric Verdin Journal: Science Date: 2012-12-06 Impact factor: 47.728
Authors: René Santer; Martina Kinner; Christoph L Lassen; Reinhard Schneppenheim; Paul Eggert; Martin Bald; Johannes Brodehl; Markus Daschner; Jochen H H Ehrich; Markus Kemper; Salvatore Li Volti; Thomas Neuhaus; Flemming Skovby; Peter G F Swift; Jürgen Schaub; Dan Klaerke Journal: J Am Soc Nephrol Date: 2003-11 Impact factor: 10.121
Authors: Frederik H Verbrugge; Petra Nijst; Matthias Dupont; Joris Penders; W H Wilson Tang; Wilfried Mullens Journal: Circ Heart Fail Date: 2014-07-18 Impact factor: 8.790
Authors: David Z I Cherney; James W Scholey; Shan Jiang; Ronnie Har; Vesta Lai; Etienne B Sochett; Heather N Reich Journal: Diabetes Care Date: 2012-07-26 Impact factor: 19.112
Authors: Julio Núñez; Patricia Palau; Eloy Domínguez; Anna Mollar; Eduardo Núñez; Jose María Ramón; Gema Miñana; Enrique Santas; Lorenzo Fácila; Jose Luis Górriz; Juan Sanchis; Antoni Bayés-Genís Journal: Clin Cardiol Date: 2018-04-17 Impact factor: 2.882